ÂÜÀòÂÒÂ×

Helen has 20 years of experience in oncology research, the majority within the DNA Damage Response (DDR) field. Since joining Artios in 2017, she’s overseen the building of the DDR biology platform and continues to lead the biology department, supporting the drug discovery process from target ID, and cell assay development to identifying and validating patient selection hypotheses.

Helen joined Artios from MISSION Therapeutics where she was both a team and project leader responsible for various drug discovery efforts up to the preclinical stage, leading both biomarker discovery and new targets functional teams.

Before moving into the biotechnology sector (including KuDOS Pharmaceuticals), Helen gained her Ph.D. from the University of Glasgow and then went on to post-doctoral training at the CRUK Beatson Institute for Cancer Research and subsequently the University of Cambridge.